Company news
Ainos, Inc. news in 2024
Ainos, Inc.'s news releases, calls and decks from 2024, newest first.
Ainos, Inc. Announces Strategic Partnership with Taiwan Tanabe Seiyaku to Advance Manufacturing and Taiwan Market Promotion of Sjögren's Syndrome Drug
December 1, 2024
Ainos Announces IRB Approval for Sjögren’s Syndrome Clinical Study at Shuang Ho Hospital, Affiliated with Taipei Medical University, and Plans to Initiate New Phase of Treatment Evaluation in Q1 2025
November 10, 2024
Ainos Reports Third Quarter 2024 Financial Results
November 5, 2024
Ainos, Inc. Receives IRB Approval From National Taiwan University Hospital for HIV-Oral Warts Clinical Trial, Highlighting Value of FDA-Designated Orphan Drug VELDONA
September 24, 2024
Ainos Announced Plan to Initiate Taiwan Clinical Study of VELDONA for Treating Sjögren's Syndrome, a Rare Disease With Limited Treatment Options
September 22, 2024
Ainos Announced Plan to Initiate Taiwan Clinical Study for VELDONA as Potential Treatment of Oral Warts in HIV-Seropositive Patients, an Orphan Drug Designated by the FDA
September 16, 2024
Ainos Secures Exclusive Multi-Regions Invention Patent Licenses from Strategic Partner to Bolster AI Nose and Point-Of-Care Testing
August 8, 2024
Ainos Concludes Growth Financing From Lind Partners
August 5, 2024
Ainos Reports Second Quarter 2024 Financial Results
August 4, 2024
Ainos Enrolls First Subject for Clinical Study of VELDONA-Based Animal FCGS Drug
July 22, 2024
Ainos Unveils Critical Progress in Ainos Flora Clinical Trials and Next-Gen Plans Powered by NVIDIA CUDA
June 13, 2024
Ainos to Initiate Clinical Study of New Potential VELDONA-Based Animal Drug, Expanding VELDONA's Potential Market
May 14, 2024
Ainos Reports First Quarter 2024 Financial Results
May 12, 2024
Ainos Raises $9 Million in Growth Capital with Existing Shareholder
May 6, 2024
Ainos Reports Full Year 2023 Financial Results
March 7, 2024
Ainos Submits Clinical Hold Complete Response to US FDA to Resolve the Deficiencies on Investigational New Drug Phase II Trial of its VELDONA Formulation Against Mild COVID-19 Symptoms
February 4, 2024
Ainos Announces $1.75 Million Follow-On Funding
January 23, 2024
Ainos Regains Compliance with Nasdaq Minimum Bid Price Requirement
January 1, 2024